Evolus, Inc. (NASDAQ:EOLS) Shares Sold by Millennium Management LLC

Millennium Management LLC decreased its holdings in Evolus, Inc. (NASDAQ:EOLS) by 4.0% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 899,377 shares of the company’s stock after selling 36,996 shares during the quarter. Millennium Management LLC owned 1.44% of Evolus worth $9,758,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of EOLS. Perceptive Advisors LLC grew its holdings in shares of Evolus by 166.8% in the 4th quarter. Perceptive Advisors LLC now owns 3,963,424 shares of the company’s stock worth $41,735,000 after acquiring an additional 2,477,623 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in shares of Evolus by 5,627.2% in the 2nd quarter. Assenagon Asset Management S.A. now owns 947,103 shares of the company’s stock valued at $10,276,000 after purchasing an additional 930,566 shares during the period. Lord Abbett & CO. LLC purchased a new position in Evolus in the 1st quarter worth about $11,628,000. Armistice Capital LLC acquired a new stake in Evolus during the 2nd quarter worth about $3,906,000. Finally, Zimmer Partners LP acquired a new stake in Evolus during the 1st quarter worth about $4,200,000. Institutional investors own 90.69% of the company’s stock.

Insider Activity

In related news, CFO Sandra Beaver sold 3,276 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $14.98, for a total transaction of $49,074.48. Following the transaction, the chief financial officer now owns 148,502 shares of the company’s stock, valued at approximately $2,224,559.96. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Evolus news, CFO Sandra Beaver sold 3,276 shares of the stock in a transaction on Friday, September 6th. The shares were sold at an average price of $14.98, for a total transaction of $49,074.48. Following the transaction, the chief financial officer now directly owns 148,502 shares of the company’s stock, valued at $2,224,559.96. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the firm’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $15.85, for a total value of $89,251.35. Following the transaction, the chief marketing officer now owns 82,375 shares in the company, valued at approximately $1,305,643.75. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.10% of the stock is owned by corporate insiders.

Evolus Stock Up 0.1 %

Evolus stock opened at $16.50 on Wednesday. Evolus, Inc. has a twelve month low of $7.44 and a twelve month high of $17.70. The company has a debt-to-equity ratio of 6.26, a quick ratio of 2.67 and a current ratio of 2.92. The firm has a market cap of $1.03 billion, a PE ratio of -15.71 and a beta of 1.31. The firm’s 50 day moving average price is $15.29 and its two-hundred day moving average price is $13.31.

Evolus (NASDAQ:EOLS) last announced its quarterly earnings data on Wednesday, July 31st. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The company had revenue of $66.91 million during the quarter, compared to analyst estimates of $65.06 million. On average, research analysts predict that Evolus, Inc. will post -0.64 EPS for the current fiscal year.

Analysts Set New Price Targets

EOLS has been the topic of several analyst reports. HC Wainwright reissued a “buy” rating and issued a $27.00 target price on shares of Evolus in a research report on Thursday, October 3rd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Evolus in a research report on Monday, September 16th. Barclays increased their target price on Evolus from $16.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, September 13th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $22.00 price target on shares of Evolus in a report on Friday, September 13th.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.